GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Gross-Profit-to-Asset %

Pharmicell Co (XKRX:005690) Gross-Profit-to-Asset % : 49.09% (As of Mar. 2025)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharmicell Co's annualized Gross Profit for the quarter that ended in Mar. 2025 was ₩50,387 Mil. Pharmicell Co's average Total Assets over the quarter that ended in Mar. 2025 was ₩102,646 Mil. Therefore, Pharmicell Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 49.09%.


Pharmicell Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharmicell Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Gross-Profit-to-Asset % Chart

Pharmicell Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.73 28.90 23.35 15.33 22.24

Pharmicell Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.29 24.87 22.44 34.09 49.09

Competitive Comparison of Pharmicell Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Pharmicell Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmicell Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's Gross-Profit-to-Asset % falls into.


;
;

Pharmicell Co Gross-Profit-to-Asset % Calculation

Pharmicell Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=21330.146/( (92518.753+99264.317)/ 2 )
=21330.146/95891.535
=22.24 %

Pharmicell Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=50386.532/( (99264.317+106027.884)/ 2 )
=50386.532/102646.1005
=49.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Pharmicell Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co Business Description

Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co Headlines

No Headlines